ArticleData in brief2025
A comprehensive metabolomic dataset of human synovial fluid in osteoarthritis and healthy controls.
Article in Data in brief, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a prevalent degenerative joint disorder that causes chronic pain and disability. The synovial fluid (SF), which bathes the joint, reflects the pathological state and is a valuable source for biomarker discovery. However, a comprehensive metabolomic profile of SF in OA remains to be fully established. Here, we present a comprehensive metabolomic dataset derived from SF samples of 10 OA patients and 10 matched healthy controls. Using non-targeted metabolomics based on ultra-high-performance liquid chromatography coupled with high-resolution mass spectrometry (UHPLC-MS), we identified 23,232 features, with 1431 metabolites annotated. Comparative analysis revealed 163 significantly differential metabolites (118 upregulated, 45 downregulated). Functional enrichment and pathway analyses highlighted disruptions in amino acid metabolism, energy metabolism, and lipid pathways. Several metabolites showed high diagnostic potential in ROC analysis. This dataset provides a valuable resource for understanding OA-associated metabolic alterations and offers robust candidate biomarkers for OA diagnosis and therapeutic monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.